Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis-Reference-Cited by-同舟云学术

Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis

Published:2019-06-24 Issue:7 Volume:10 Page:1068-1073
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Jiang Zhigan¹^ORCID,Liu Xing²,Yuan Zhiliang¹,He Haiying¹,Wang Jing¹,Zhang Xiao¹,Gong Zhen¹,Hou Lijuan¹,Shen Liang¹,Guo Fengxun¹,Zhang Jiliang¹,Wang Jianhua¹,Xu Deming¹,Liu Zhuowei²³,Li Haijun²³,Chen Xiaoxin²³,Long Chaofeng²³,Li Jian¹,Chen Shuhui¹

Affiliation:

1. WuXi AppTec (Shanghai) Co., Ltd, 288 FuTe Zhong Road, Shanghai 200131, P. R. China

2. R&D Center, Guangdong Zhongsheng Pharmaceutical Co., Ltd. The Information Area of Xihu Industrial Base, Shilong Town, Dongguan, Guangdong Province 523325, P. R. China

3. Guangdong Raynovent Biotech Co., Ltd., Room 1701-1705, Main Building of Rongyi Tower, No. 5, Xinxi Road, SongShan Lake Hi-tech Industrial Development Zone, Dongguan, Guangdong Province 523808, P. R. China

Funder

Ministry of Science and Technology of the People's Republic of China

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.9b00189

Reference44 articles.

1. Primary biliary cirrhosis

2. Primary Biliary Cirrhosis

3. Ursodeoxycholic acid: Mechanism of action and novel clinical applications

4. Primary biliary cirrhosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020–2023);Expert Opinion on Therapeutic Patents;2024-02

2. Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases;Journal of Medicinal Chemistry;2023-05-27

3. Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications;Pharmaceutics;2022-10-08

4. PPARα: A potential therapeutic target of cholestasis;Frontiers in Pharmacology;2022-07-18

5. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis;Journal of Medicinal Chemistry;2022-01-21